Plasma Level of Homocysteine Associated with Severe Vertebral Fracture in Postmenopausal Women

[1]  C. Cisari,et al.  The assessment of vertebral fractures in elderly women with recent hip fractures: the BREAK Study , 2013, Osteoporosis International.

[2]  K. Oumghar,et al.  Homocysteine, folate, and vitamin B12 levels and vertebral fracture risk in postmenopausal women. , 2012, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[3]  Shiro Tanaka,et al.  Urinary pentosidine improves risk classification using fracture risk assessment tools for postmenopausal women , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  M. Shiraki,et al.  Effects of bone mineral density of the lumbar spine and prevalent vertebral fractures on the risk of immobility , 2010, Osteoporosis International.

[5]  R. Chapurlat,et al.  Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study , 2010, Osteoporosis International.

[6]  M. Saito,et al.  Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus , 2010, Osteoporosis International.

[7]  R. Abouqal,et al.  Relationship between historical height loss and vertebral fractures in postmenopausal women , 2009, Clinical Rheumatology.

[8]  S. Cummings,et al.  Pentosidine and increased fracture risk in older adults with type 2 diabetes. , 2009, The Journal of clinical endocrinology and metabolism.

[9]  Y. Kiyohara,et al.  Prevalence of chronic kidney disease in the Japanese general population , 2009, Clinical and Experimental Nephrology.

[10]  Britt Wildemann,et al.  Hyperhomocysteinemia induces a tissue specific accumulation of homocysteine in bone by collagen binding and adversely affects bone. , 2009, Bone.

[11]  T. Hansson,et al.  The prognosis for pain, disability, activities of daily living and quality of life after an acute osteoporotic vertebral body fracture: its relation to fracture level, type of fracture and grade of fracture deformation , 2008, European Spine Journal.

[12]  Satoshi Inoue,et al.  The synergistic effect of bone mineral density and methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) on fractures , 2008, Journal of Bone and Mineral Metabolism.

[13]  S. Yano,et al.  Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. , 2008, The Journal of clinical endocrinology and metabolism.

[14]  M. Fukunaga,et al.  Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures , 2008, Journal of Bone and Mineral Metabolism.

[15]  M. Hannan,et al.  B vitamins, homocysteine, and bone disease: Epidemiology and pathophysiology , 2007, Current osteoporosis reports.

[16]  C. Roux,et al.  Mild prevalent and incident vertebral fractures are risk factors for new fractures , 2007, Osteoporosis International.

[17]  H. Genant,et al.  Enhanced prediction of fracture risk combining vertebral fracture status and BMD , 2007, Osteoporosis International.

[18]  M. Saito,et al.  Degree of Mineralization-related Collagen Crosslinking in the Femoral Neck Cancellous Bone in Cases of Hip Fracture and Controls , 2006, Calcified Tissue International.

[19]  H. Genant,et al.  Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. , 2005, The Journal of clinical endocrinology and metabolism.

[20]  S. Silverman,et al.  Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. , 2004, Arthritis and rheumatism.

[21]  O Johnell,et al.  A meta-analysis of previous fracture and subsequent fracture risk. , 2004, Bone.

[22]  A. Hofman,et al.  Homocysteine levels and the risk of osteoporotic fracture. , 2004, The New England journal of medicine.

[23]  H. Genant,et al.  Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. , 2003, Bone.

[24]  D. Barrio,et al.  Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress , 2001, BMC Cell Biology.

[25]  A. Boskey,et al.  Homocysteine decreases chondrocyte-mediated matrix mineralization in differentiating chick limb-bud mesenchymal cell micro-mass cultures. , 2001, Bone.

[26]  Susan R. Johnson,et al.  Osteoporosis prevention, diagnosis, and therapy. , 2001, JAMA.

[27]  T. Abbott,et al.  Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical Synthesis , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  H. Jakubowski.  Calcium-dependent Human Serum Homocysteine Thiolactone Hydrolase , 2000, The Journal of Biological Chemistry.

[29]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[30]  S. Cummings,et al.  Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis , 1996 .

[31]  H. Blom,et al.  Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. , 1996, Biochimica et biophysica acta.

[32]  R. Epstein,et al.  Pre-existing fractures and bone mass predict vertebral fracture incidence in women. , 1991, Annals of internal medicine.

[33]  L. Palermo,et al.  Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture Trial , 2011, Osteoporosis International.

[34]  Shiro Tanaka,et al.  Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment , 2010, Journal of Bone and Mineral Metabolism.

[35]  Shiro Tanaka,et al.  Contributions of 25-hydroxyvitamin D, co-morbidities and bone mass to mortality in Japanese postmenopausal women. , 2009, Bone.

[36]  B. Vester,et al.  High Performance Liquid Chromatography Method for Rapid and Accurate Determination of Homocysteine in Plasma and Serum , 1991, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.